Nordwand Advisors’s Cellectar Biosciences CLRB Stock Holding History

Nordwand Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-667	Closed	-$6.31K	–	184
2025 Q1	$6.31K	Buy	+667	New	+$6.04K	﹤0.01%	88

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

RCA

Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Nordwand Advisors's CLRB Position: Q2 2025 in Review

Nordwand Advisors sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 667 shares — an estimated $6.31K sold.

Nordwand Advisors first reported a position in CLRB in Q1 2025 and held it in 1 quarter. The position peaked at $6.31K in Q1 2025. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

Nordwand Advisors reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
Nordwand Advisors sold 667 Cellectar Biosciences shares in Q2 2025, an estimated $6.31K.
Nordwand Advisors first reported a position in Cellectar Biosciences in Q1 2025 and held it in 1 quarter.
Nordwand Advisors's Cellectar Biosciences position peaked at $6.31K in Q1 2025.
19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on Nordwand Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.